The company has developed LMS-611 from its proprietary inhaled Lamellasome delivery platform.
With this milestone, the company expects to get investment and development partners for advancing the drug into clinical use.
Lamellar chief business officer Iain McDougall said the designation of LMS-611 as an orphan drug by the European Medicines Agency underscores the importance of developing effective treatments for patients with cystic fibrosis.
"To date we have been extremely encouraged by LMS-611’s preclinical results, and we continue to believe we are developing a therapy which will prove to be both safe and effective with the potential to offer a brand new way of treating the disease when we enter clinical trials early next year," McDougall said.